OncoMatch/Clinical Trials/NCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Is NCT06533579 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for b-cell acute lymphoblastic leukemia.

Phase 1/2RecruitingVironexis Biotherapeutics Inc.NCT06533579Data as of May 2026

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia

Hodgkin Lymphoma

Acute Myeloid Leukemia

Biomarker criteria

Required: CD19 positive expression (positive)

CD19-positive expression

Prior therapy

Min 1 prior line

Must have received:

Relapsed or refractory CD-19 positive leukemia or lymphoma

Cannot have received: chemotherapy

Exception: given within the protocol-specified discontinuation timelines

Chemotherapy given within the protocol-specified discontinuation timelines

Lab requirements

Blood counts

protocol-specified ranges

Kidney function

protocol-specified ranges

Liver function

AST or ALT ≤ 2x upper limit of normal

Cardiac function

protocol-specified ranges

Protocol-specified ranges for renal, liver, cardiac and pulmonary function; Protocol-specified ranges for hematology parameters; Hepatoxicity (AST or ALT > 2x upper limit of normal) [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

City of Hope · Duarte, California
Valkyrie Clinical Trials · Los Angeles, California
Colorado Blood Cancer Institute · Denver, Colorado
New York Medical College · Valhalla, New York
University of North Carolina at Chapel Hill/ University of North Carolina Medical Center · Chapel Hill, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify